Clinical Course of Lamivudine Monotherapy in Patients with Decompensated Cirrhosis due to HBeAg negative chronic HBV infection - Concepedia

Concepedia

Publication | Closed Access

Clinical Course of Lamivudine Monotherapy in Patients with Decompensated Cirrhosis due to HBeAg negative chronic HBV infection

72

Citations

22

References

2004

Year

Spilios Manolakopoulos, Stylianos Karatapanis, Jiannis Elefsiniotis, Nicoletta Μathou, Jiannis Vlachogiannakos, Elissabet Iliadou, Anastasios Kougioumtzan, Michalis Economou, Christos Triantos, Dimitrios Tzourmakliotis,

The American Journal of Gastroenterology

Abstract

Lamivudine significantly improves liver function in HBeAg-negative decompensated cirrhosis. However, the development of the biochemical breakthrough due to YMDD mutants is associated with fatal outcome.

References

	Year	Citations

Page 1